{"product_id":"avantorsciences-swot-analysis","title":"Avantor SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAvantor combines a robust life-sciences distribution network and strong R\u0026amp;D partnerships with scale advantages in laboratory consumables, but faces margin pressure from raw-material costs and intense competition in specialty chemicals.\u003c\/p\u003e\n\u003cp\u003eDiscover the complete picture behind Avantor’s market position with our full SWOT analysis—an editable, investor-ready report (Word + Excel) delivering research-backed insights, strategic takeaways, and financial context to support smarter decisions; purchase to unlock the full report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeep Integration in Bioprocessing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvantor supplies high-purity reagents and single-use systems to the world’s top biopharma firms, creating high switching costs—its life sciences segment reported $7.3B revenue in 2024, ~62% of total sales, showing deep workflow embedment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Proprietary Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvantor owns trusted brands like J.T.Baker and Masterflex that support premium pricing; proprietary portfolio sales contributed roughly 42% of product revenue in 2024, boosting gross margins above company average.\u003c\/p\u003e\n\u003cp\u003eThese owned products typically deliver higher gross margins than third-party goods—by about 6–8 percentage points in 2024—creating a measurable competitive moat through pricing power.\u003c\/p\u003e\n\u003cp\u003eOwning IP lets Avantor control quality and shorten innovation cycles; R\u0026amp;D and product development spending rose to $85 million in 2024 to accelerate new proprietary launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Recurring Revenue Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpa substantial portion of avantor revenue its billion sales from consumables and mission supplies that customers replenish regularly creating predictable resilient cash flow recurring helped report a organic growth in fy2024 kept adjusted ebitda margins stable near reducing volatility vs. capital peers.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpavantor operates in over countries with a logistics network supporting skus for life and advanced customers enabling localized inventory avg. hour regional delivery sensitive reagents chemicals.\u003e\n\u003cpthis scale trims per supply costs helped drive revenue of billion and lets avantor absorb regulatory burden across markets a high barrier for smaller rivals.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30+ countries presence\u003c\/li\u003e\n\u003cli\u003e3,500+ SKUs managed\u003c\/li\u003e\n\u003cli\u003e48–72h regional delivery\u003c\/li\u003e\n\u003cli\u003e$7.7B revenue (2024)\u003c\/li\u003e\n\u003cli\u003eRegulatory compliance as barrier\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pavantor\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMission-Critical Necessity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpavantor supplies non-discretionary consumables for labs and healthcare bioprocess materials single-use plastics diagnostics vaccine production so demand is steady even in downturns life sciences accounted of revenue avantor providing insulation. research spending biomanufacturing growth biologics market growing cagr recurring sales.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e~55% revenue from healthcare \u0026amp; life sciences (2024)\u003c\/li\u003e\n\u003cli\u003eHigh recurring consumable mix\u003c\/li\u003e\n\u003cli\u003eDemand tied to diagnostics \u0026amp; vaccine production\u003c\/li\u003e\n\u003cli\u003eBiologics market ~11% CAGR 2023–2028\u003c\/li\u003e\n\n\u003c\/pavantor\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvantor: Life‑science powerhouse—$7.3B, 42% proprietary mix, 16% EBITDA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvantor’s life‑science focus drove $7.3B in segment sales (2024), ~62% of total; proprietary brands (J.T.Baker, Masterflex) made ~42% of product revenue, lifting gross margins ~6–8ppt; recurring consumables gave 7% organic growth and adjusted EBITDA ~16% in FY2024; global ops (30+ countries, 3,500+ SKUs) enable 48–72h delivery and regulatory scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLife‑science revenue\u003c\/td\u003e\n\u003ctd\u003e$7.3B (62%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$9.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProprietary product mix\u003c\/td\u003e\n\u003ctd\u003e~42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBITDA margin\u003c\/td\u003e\n\u003ctd\u003e~16%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganic growth\u003c\/td\u003e\n\u003ctd\u003e7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries \/ SKUs\u003c\/td\u003e\n\u003ctd\u003e30+ \/ 3,500+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear SWOT framework for analyzing Avantor’s business strategy, mapping its operational strengths and capabilities, internal weaknesses, external market opportunities, and competitive threats that shape its growth trajectory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise Avantor SWOT snapshot for rapid strategic alignment and stakeholder-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Debt Obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvantor had net leverage around 3.0x net debt\/EBITDA as of FY 2024 (company 10-K filed Feb 14, 2025), reflecting past acquisitive growth; interest expense totaled about $345 million in 2024, consuming a material share of operating cash flow and crowding out potential R\u0026amp;D spend.\u003c\/p\u003e\n\u003cp\u003eDespite active deleveraging—net debt fell roughly $500 million from 2023 to 2024—high fixed obligations still restrict capital allocation and reduce flexibility if interest rates rise or a recession cuts revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Biopharma R\u0026amp;D Cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvantor is highly sensitive to biopharma funding cycles: US biotech VC deal value fell 32% to $26.8B in 2024 versus 2021, and IPO activity dropped sharply, reducing clients’ capital for R\u0026amp;D and lab spend.\u003c\/p\u003e\n\u003cp\u003eWhen VC or public funding slows, customers postpone projects and cut consumables and equipment orders, driving revenue volatility; Avantor reported organic growth slowing to 1.2% in Q4 2024, reflecting this pressure.\u003c\/p\u003e\n\u003cp\u003eThese swings create revenue periods outside Avantor’s control, increasing forecasting difficulty and margin compression during funding troughs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSegment Margin Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Lab Solutions segment faces tougher competition and lower gross margins—about 18–20% in 2024 versus Bioscience Production’s 28–32%—so shifts toward third-party distribution can drag consolidated margin by several hundred basis points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustomer Concentration Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eA significant share of Avantor’s 2024 revenue—about 28% of $6.7 billion—comes from a small set of large biopharma and healthcare customers, so losing a single major contract or a volume drop would hit margins and cash flow hard.\u003c\/p\u003e\n\u003cp\u003eThat concentration gives those buyers strong negotiating leverage, pressuring pricing and service terms and raising renewal risk; a 10% volume decline at one top account could cut consolidated revenue by roughly 2.8%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~28% of 2024 revenue from top large accounts\u003c\/li\u003e\n\u003cli\u003eLoss of one major client ≈ −2.8% revenue impact\u003c\/li\u003e\n\u003cli\u003eHigh buyer bargaining power on pricing\/terms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex Integration Challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAvantor’s frequent acquisitions have left it with fragmented IT systems and cultures; as of FY2024 revenue of $9.2B, integration delays contributed to a 120–150 bps drag on adjusted EBITDA margin in parts of 2023–24.\u003c\/p\u003e\n\u003cp\u003eFailure to harmonize teams raises admin costs and slows procurement and R\u0026amp;D support; global headcount of ~14,000 complicates standardizing processes and platforms.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMultiple ERP platforms across regions\u003c\/li\u003e\n\u003cli\u003e~$50–80M annual integration run-rate\u003c\/li\u003e\n\u003cli\u003e14,000 employees complicate rollout\u003c\/li\u003e\n\u003cli\u003e120–150 bps EBITDA margin impact\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh leverage, weak organic growth and cost drag threaten margins and concentration risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh leverage (net debt\/EBITDA ~3.0x in FY2024) and $345M interest cost constrain R\u0026amp;D and flexibility; organic growth slid to 1.2% in Q4 2024 amid weaker biopharma funding (US VC deal value $26.8B in 2024). Lab Solutions margins (~18–20%) trail Bioscience Production (28–32%), and ~28% of 2024 revenue concentrated in few large accounts (loss ≈ −2.8% revenue). Fragmented IT\/ERP and ~14,000 staff force a 120–150 bps EBITDA drag.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (FY2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet leverage\u003c\/td\u003e\n\u003ctd\u003e~3.0x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest expense\u003c\/td\u003e\n\u003ctd\u003e$345M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganic growth Q4\u003c\/td\u003e\n\u003ctd\u003e1.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS biotech VC (2024)\u003c\/td\u003e\n\u003ctd\u003e$26.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue concentration\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab Solutions margin\u003c\/td\u003e\n\u003ctd\u003e18–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioscience Production margin\u003c\/td\u003e\n\u003ctd\u003e28–32%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eERP\/headcount\u003c\/td\u003e\n\u003ctd\u003eMultiple platforms \/ ~14,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA drag\u003c\/td\u003e\n\u003ctd\u003e120–150 bps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eAvantor SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.\u003c\/p\u003e\n\u003cp\u003eThis is a real excerpt from the complete document. Once purchased, you’ll receive the full, editable version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752830742905,"sku":"avantorsciences-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/avantorsciences-swot-analysis.png?v=1772246174","url":"https:\/\/growthsharematrix.com\/products\/avantorsciences-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}